PHARMACY

Novo Nordisk to develop investigational diabetes treatment

BY Alaric DeArment

BAGSVAERD, Denmark Novo Nordisk has started an early-stage clinical trial in the United Kingdom of an investigational drug for treating diabetes, the Danish drug maker announced Wednesday.

Under the terms of an agreement with Cedar Knolls, N.J.-based drug maker Emisphere Technologies, it made a $2 million milestone payment for the phase 1 trial of NN9924, which was developed using Emisphere’s Eligen drug-development platform. Novo Nordisk expects to report results from the 155-patient trial in 2011.

The drug is a pill-based GLP-1 analog, belonging to the same class as Novo Nordisk’s Victoza (liraglutide). GLP-1 is a natural hormone that controls blood sugar levels by stimulating the release of insulin only when blood sugar levels become too high. People with Type 2 diabetes often have an impaired ability to produce the hormone.

“We still have a long road with many challenges ahead of us before a GLP-1 pill becomes a reality,” Novo Nordisk SVP and head of diabetes research Peter Kurtzhals said in a statement. “But with the progress we have made so far, I am convinced it is only a matter of time before we make it.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Study: Some African-American diabetics at risk of developing retinal disease

BY Alaric DeArment

NEW YORK African-American diabetics who consume large amounts of calories and sodium risk developing more severe retinal disease than those who don’t, according to a study published in the January issue of Archives of Ophthalmology.

Researchers at the New York University College of Dentistry and the New Jersey Medical School at the University of Medicine and Dentistry of New Jersey examined 469 African-American patients with Type 1 diabetes who enrolled in the study between 1993 and 1998, administering eye exams, blood tests and a diet questionnaire after a six-year follow-up.

Those with the highest caloric intake at the beginning of the study were more likely to develop retinopathy leading to vision loss by the end of the six-year period, while those with high sodium intake had the highest risk of developing macular edema.

“In African American patients with Type 1 diabetes, high caloric and sodium intakes are significant and independent risk factors for progression to severe forms of diabetic retinopathy,” the authors wrote. “These results suggest that low caloric and sodium intakes in African American individuals with Type 1 diabetes mellitus may have a beneficial effect on the progression of diabetic retinopathy and thus might be part of dietary recommendations for this population.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Google.org to expand Google Flu Trends tracking

BY Michael Johnsen

MOUNTAIN VIEW, Calif. Google.org on Tuesday announced on its blog site that it is expanding its Google Flu Trends tracking capabilities from the macro to the micro.

“We’ve been chatting with public health officials about new ways we can help people understand the spread of flu during this unusual time and today we’re excited to bring city level flu estimates to 121 cities in the United States,” the company wrote in its blog.

The city level estimates are “experimental,” the company cautioned, meaning they haven’t been validated against official data. However, the estimates are made in a similar manner to its U.S. national estimates, which have been validated.

In contrast to the unusually early spike of flu activity this October, Google Flu Trends is currently showing a low level of activity in the United States.

Google Flu Trends helps estimate flu trends in real time by tracking the popularity of certain Google search queries.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?